HALOTEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALOTEX (HALOTEX).
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
| Metabolism | Haloprogin is primarily metabolized in the liver via oxidation and conjugation, with minimal systemic absorption following topical application. |
| Excretion | Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%). |
| Half-life | Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Not established; likely low due to high protein binding and lipophilicity. |
| Bioavailability | Topical: negligible systemic absorption (<0.5% of applied dose); oral: not available. |
| Onset of Action | Topical: relief of pruritus and improvement in lesions typically within 24-72 hours of application. |
| Duration of Action | Topical: symptomatic improvement persists as long as treatment continues; recurrence common without adequate course (typically 2-4 weeks). |
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment needed; topical use with minimal systemic absorption. |
| Liver impairment | No adjustment needed; topical use with minimal systemic absorption. |
| Pediatric use | Safety not established; use only if clearly needed. |
| Geriatric use | No specific adjustments; monitor for irritation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HALOTEX (HALOTEX).
| Breastfeeding | It is not known whether haloprogin is excreted in human milk. Because of minimal systemic absorption, risk to nursing infant is likely low. Caution is advised. M/P ratio not available. |
| Teratogenic Risk | Haloprogin (HALOTEX) is a topical antifungal. Systemic absorption is minimal, and no teratogenic effects have been reported in animal studies. There are no adequate well-controlled studies in pregnant women. Risk to the fetus is considered low when applied topically as directed. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to haloprogin or any component of the formulation.
| Precautions | For external use only. Avoid contact with eyes and mucous membranes. Discontinue if irritation or sensitization occurs. Use with caution in patients with known hypersensitivity to haloprogin or any component of the formulation. |
Loading safety data…
| No specific maternal or fetal monitoring is required for topical haloprogin use. Observe for local irritation or allergic reaction. |
| Fertility Effects | No known effects on fertility based on limited data. Systemic absorption is negligible. |